Quick answer
Chinese medicine in cancer care is often assumed to be a last resort for patients out of options. The oncology department at Guang'anmen Hospital argues the opposite: that it belongs across the whole pathway, from nodule surveillance to postoperative rehabilitation. Its head, Hou Wei, states that compared with Western treatment alone, integrated Chinese and Western treatment reduced the two-year postoperative recurrence and metastasis rate in lung cancer by about 6% [1][2][3][5].
Key takeaways
- The department has more than 60 years of history and now records 300,000 outpatient visits a year [1].
- Three generations of theory: Fuzheng Peiben (support the upright and consolidate the root), then Fuzheng Jiedu, then Guben Qingyuan [1].
- Reported effect: about a 6 percentage-point reduction in two-year postoperative recurrence and metastasis in lung cancer [1][2].
- A cancer-prevention clinic manages pulmonary nodules, thyroid nodules and colon polyps [1][5].
- In advanced disease, the department reports a median survival gain of 3.47 months and a 15.5% improvement in quality-of-life scores [5].
What "integrative" means here
The model is not TCM instead of oncology; it is TCM alongside it, with the Western part determining the disease strategy and the Chinese part addressing the patient's constitution and the side effects of treatment. For a resected lung cancer, that means standard adjuvant therapy plus herbal formulae chosen by pattern; for chemotherapy-induced nausea and neutropenia, spleen-warming and qi-tonifying herbs; for radiation mucositis and dermatitis, heat-clearing and moistening formulae used internally and as rinses [1][4][5].
The department also runs a prevention clinic that follows incidental nodules. High-risk nodules get shorter surveillance intervals and referral to thoracic surgery or imaging when malignancy is suspected; low-risk ones are managed with pattern-based herbs aimed at improving the local environment [1][5].
How strong is the evidence
A 6 percentage-point absolute reduction in two-year recurrence is a clinically relevant effect size — comparable to what some adjuvant interventions achieve. But it is reported as a department-level summary rather than a named trial with a citation, sample size or confidence interval [1][2].
Chinese integrative oncology has produced genuine randomised trials — the Fuzheng herbal literature includes several — but these are typically single-centre, unblinded and rely on pattern-based prescribing that is hard to standardise. The 6% figure, as published here, comes from an interview rather than a paper, and cannot be verified or replicated from the source. Treat it as a hypothesis supported by institutional experience, not as an established effect size [1][5].
The condition in context: lung cancer in China
Lung cancer is the leading cause of cancer death in China, and recurrence after resection is common.
| Region | What the data shows | Source |
|---|---|---|
| Scale | The department alone sees 300,000 outpatient visits a year [1]. | Xinhua [1] |
| Recurrence | Postoperative relapse drives most lung-cancer mortality, which is why adjuvant strategies matter [1]. | Xinhua [1] |
| Guidance | The department led a national expert consensus on integrated diagnosis and treatment of NSCLC [5]. | Ruli [5] |
Because adjuvant chemotherapy adds only a few percentage points of cure, a similarly sized effect from a low-toxicity adjunct would be meaningful if confirmed [1].
Why it matters
| For the patient | What the profile suggests | Source |
|---|---|---|
| Side-effect control | Herbal and external treatments for chemotherapy and radiotherapy toxicity [1]. | [1] |
| Surveillance | A dedicated nodule clinic with surgical referral pathways [1][5]. | [1][5] |
| Caution | Herb-drug interactions and unverified effect sizes [2]. | [2] |
Availability and limits
- This is an editorial profile of hospital and media reports, not a treatment recommendation [1][2].
- The 6% figure is not linked to a named published trial in the source [1].
- Herbal formulae must be prescribed by an experienced oncology-trained TCM physician [5].
- Some herbs interact with chemotherapy and targeted agents [2].
- Outcomes depend on the underlying Western treatment being optimal [1].
What to ask before booking
| Question | Why it matters |
|---|---|
| Which published trial supports the recurrence figure? | Effect sizes need a source to be judged [1]. |
| Could the herbs interact with my adjuvant therapy? | Interaction risk is real and under-studied [2]. |
| Which department handles foreign patients, and in what language? | Guang'anmen is a working hospital we do not book; confirm international-department coordination and language support. |
| Does the plan replace or accompany standard oncology? | It is explicitly adjunctive [1]. |
Questions patients ask
What is the reported effect?
About a 6 percentage-point reduction in two-year postoperative recurrence and metastasis in lung cancer with integrated Chinese and Western treatment versus Western treatment alone, as stated by the department head [1][2].
What does integrated treatment involve?
Standard oncological treatment plus pattern-based herbal formulae and external therapies aimed at constitution, side effects and rehabilitation [1][5].
Is there a published trial?
The figure is given in an interview rather than tied to a specific published trial in the source, so it cannot be verified from that alone [1].
How large is the department?
More than 60 years of history, with 300,000 outpatient visits a year [1].
Is this relevant to international patients?
It is useful context for China's integrative oncology. Guang'anmen is a working hospital we do not book — contact its international department directly [1].